Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12691221-B2
Publication Date
2026-07-28
Expiration Date
Abstract
A method of facilitating delivery of a discretionary dose of insulin to a user includes: enabling the user or a caregiver to specify, via a computer-based user interface, parameters associated with a discretionary delivery of insulin that may be delivered to the user; subsequently receiving data that represents the user's glucose level during a period of time associated with the discretionary delivery; automatically determining, with a computer-based processor, based on the received data, if, when and how much discretionary insulin should be delivered to the user during the period of time associated with the discretionary delivery; delivering insulin to the user during the period of time associated with the discretionary delivery according to the automatic determination; and delivering insulin to the user with the insulin delivery device according to a non-discretionary insulin delivery schedule unless a discretionary insulin delivery mode has been triggered.
Core Innovation
The method receives user input defining parameters for a discretionary insulin delivery mode. In response to an event associated with the user, the system determines lower and upper basal-rate thresholds relative to the constant basal rate of a non-discretionary schedule. It delivers discretionary insulin according to a variable basal rate within those thresholds, ceases the mode based on tracked discretionary insulin and a received glucose value, and resumes delivery under the unadjusted non-discretionary schedule.
The system illustrates discretionary insulin delivery behavior using glucose traces, forecasts, basal-rate adjustments, and insulin-on-board constraints. It provides augmented basal delivery when conditions permit and attenuation when projected glucose is below target, along with dosing limits and mode cessation. Because the background section is omitted, the underlying problem being solved is not explicitly described in patent.
Claims Coverage
The claim coverage comprises four inventive features directed to independent claim 1 and dependent claims 2–6.
User-defined discretionary insulin delivery mode
The system receives user input defining parameters for a mode in which it is permitted to deliver discretionary insulin without further user input, according to a variable basal rate between upper and lower threshold basal rates in response to user-associated events.
Event-responsive basal-rate thresholds
In response to an event associated with the user, the system sets a lower threshold to a basal rate below the constant rate of the non-discretionary schedule and an upper threshold to that constant rate plus a basal rate determined based on the event.
Variable-rate discretionary insulin delivery
The system delivers discretionary insulin according to the variable basal rate between the thresholds, with dependent claims specifying that delivery occurs in addition to, or in place of, insulin under the non-discretionary schedule.
Mode cessation and return to scheduled delivery
Based on tracked discretionary insulin and a received glucose value, the system ceases the discretionary mode and resumes delivery under the non-discretionary schedule at its constant basal rate, with dependent claims specifying cessation upon dose completion, delivery of a parameter-defined maximum amount within a time period, or achievement of a desired glucose level.
The independent claim covers user-defined, event-responsive discretionary insulin delivery at a variable basal rate with thresholds set relative to a constant non-discretionary rate and a return to the unadjusted schedule, while dependent claims specify supplementation, replacement, and cessation conditions.
Stated Advantages
Not explicitly described in patent.
Documented Applications
A system configured to deliver insulin to a user, including discretionary insulin delivery alongside or instead of a non-discretionary insulin delivery schedule.
Interested in licensing this patent?